Alkermes Plc
NASDAQ:ALKS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alkermes Plc
NASDAQ:ALKS
|
IE |
|
S
|
SGF Capital PCL
SET:SGF
|
TH |
|
P
|
Provention Bio Inc
F:2VB
|
US |
|
CML Microsystems Plc
LSE:CML
|
UK |
|
B
|
Baijiayun Group Ltd
NASDAQ:RTC
|
CN |
|
California Style Palms Inc
OTC:CFPI
|
US |
|
S
|
Sen X PCL
SET:SENX
|
TH |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
CA |
|
CloudMD Software & Services Inc
XTSX:DOC
|
CA |
|
Redstone Resources Ltd
ASX:RDS
|
AU |
|
F
|
FN Factory Outlet PCL
SET:FN
|
TH |
Wall Street
Price Targets
ALKS Price Targets Summary
Alkermes Plc
According to Wall Street analysts, the average 1-year price target for
ALKS
is 44.4 USD
with a low forecast of 30.3 USD and a high forecast of 60.9 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ALKS's stock price target?
Price Target
44.4
USD
According to Wall Street analysts, the average 1-year price target for
ALKS
is 44.4 USD
with a low forecast of 30.3 USD and a high forecast of 60.9 USD.
What is Alkermes Plc's Revenue forecast?
Projected CAGR
12%
For the last 11 years the
compound annual growth rate for
Alkermes Plc's revenue is
8%.
The projected
CAGR
for the next 3 years is
12%.
What is Alkermes Plc's Operating Income forecast?
Projected CAGR
7%
The
compound annual growth rate
of Alkermes Plc's operating income for the next 3 years is
7%.
What is Alkermes Plc's Net Income forecast?
Projected CAGR
3%
The
compound annual growth rate
of Alkermes Plc's net income for the next 3 years is
3%.
